WJ
Wouter Joustra
General Partner at Forbion
Amsterdam, North Holland
Overview
Wouter Joustra is currently a General Partner at Forbion, where he oversees investments in Series B stage BioTech companies. With a track record of successful board memberships and investments, he played a key role in the sale of Aiolos Bio to GSK for up to $1.4 billion and Gyroscope Therapeutics to Novartis for up to $1.5 billion.
Work Experience
General Partner
2020 - Current
FEAC Board Director (NASDAQ now: ENGN)
2021 - 2023
De-SPAC with Engene, NASDAQ: ENGN
Partner
2019 - 2020
Board Member
2024
Board Member
2024
Board Member (NASDAQ: NAMS)
2024
Board Member (Observer) (NASDAQ: NAMS)
2021 - 2024
Board Member (NASDAQ: ENGN)
2024
Board Member
2023
Board Member & Founding Investor - Sold to GSK for up to $1.4bn
2023 - 2024
Aiolos Bio is a biotech company developing innovative therapies for respiratory diseases and immune conditions.
Raised $245,000,000.00 from Forbion Capital Partners, Atlas Venture, Sofinnova Investments, RA Capital Management and Bain Capital Life Sciences.
Board Member (NASDAQ: VECT) - Sold to Ironwood for $1.2bn
2022 - 2023
Board Member - Sold to Novartis for up to $1.5bn
2021 - 2022
Executive Boardmember Life Sciences Franchise
2017 - 2019
Senior Life Sciences Trader
2016 - 2019
• Actively running Kempen’s Life Sciences portfolio • Specialized in European Life Sciences & Biotech • Involved in deal structuring, equity capital market transactions, crossing large blocks of company shares (for example placed >€150mln notional in Argenx at market levels in 2019), deal structuring through warrants/derivatives • Developed an extensive network with both corporates, and specialized investors